Optimization treated clinical research for Iodine-131–Labeled Metuximab Injection Combined with Chemoembolization for HCC

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001556

Enrollment

Unknown

Registered

2011-09-14

Start date

2011-05-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HCC

Interventions

Different Groups:Iodine-131–Labeled Metuximab Injection Combined with Chemoembolization

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Voluntary and signed the agreement in writing informed; 2. Primary liver cell liver cancer patients confirmed by the CT scan and tumor markers (AFP) test or pathology examination; 3. To be physically KPS score 60 minute acuity; 4. Without liver and kidney function serious obstacle money (A and B level), not the patient vein obstruction, tumor occupy completely rate < 70%.

Exclusion criteria

Exclusion criteria: 1. general condition is poor, liver meritorious service is significantly impaired (> 3 times the normal bilirubin cap, serum albumin < 30 g/L); 2. complicated with serious heart, kidney and blood system disease patients; 3. compliance dealing; 4. have biological agents allergy history, allergic constitution or is in a state of allergy patients; 5. pregnancy and lactation women.

Design outcomes

Primary

Measure	Time frame
TTP;OS;	—

Countries

China

Contacts

Public ContactShen Bin

binshen_hoist@yahoo.com.cn+86 028 66537310

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026